Combining anti tumor drugs with chemo may improve rare children’s cancer outcomes скачать в хорошем качестве

Combining anti tumor drugs with chemo may improve rare children’s cancer outcomes

#cancertreatment #neuroblastoma #bevacizumab Combining anti-tumor drugs with chemo may improve rare children’s cancer outcomes Children who develop neuroblastomas, a rare form of cancer which develops in nerve cells, may benefit from receiving certain anti-tumour drugs as well as chemotherapy, a new trial has found. The results of the BEACON trial conducted by the Cancer Research UK Clinical Trials Unit at the University of Birmingham found that combining anti-angiogenic drugs, which block tumours from forming blood vessels, alongside various chemotherapy drugs led to more young people seeing their tumours shrinking, from 18% in the control group to 26% among those on Bevacizumab. The findings are published in the Journal of Clinical Oncology today. The trial saw 160 young people aged 1-21, from 43 hospitals in 11 European countries, randomised with half receiving the anti-angiogenic drug called Bevacizumab on top of conventional therapy. The group who received Bevacizumab had an increase in the likelihood of responding to treatment, from 18% among those who only had the established therapy to 26% for those with the additional drug. Patients who received Bevacizumab additionally had better one year progression-free survival rates. The trial constituted one of many collaborations between the University of Birmingham and European expert groups SIOPEN (International Society of Paediatric Oncology European Neuroblastoma) and ITCC (Innovative therapies for children with cancer). These are very exciting results that hopefully get us closer to finding treatments for children who develop neuroblastomas. Currently, the outcomes are really poor for children who get this horrible cancer and so even seemingly small increases in the chance that a patient is going to be able to shrink their tumours is significant. “We are delighted that the BEACON trial has helped to shape treatment for children with relapsed and refractory neuroblastoma going forward.” Check full updates on Medical Dialogues Also check out - Medical Dialogues Academy, a renowned academic wing of Medical Dialogues - India's premier health and news online portal, proudly presents this comprehensive course tailored for healthcare professionals eager to delve into the realm of medical journalism. 🔗 Enroll Today: https://academy.medicaldialogues.in/c... 📚 Explore More With Us: 📌 Medical Content Writing: https://academy.medicaldialogues.in/c... 📌 Certificate Course in Pharmaceutical Medico-Marketing: https://academy.medicaldialogues.in/c... Join us on this enlightening journey and become a part of a community pushing the boundaries of healthcare communication and reporting. Get the latest medical and health news at medicaldialogues.in Follow us on Twitter:   / medicaldialogs   Facebook:   / medicaldialogues   Instagram:   / medicaldialogues   LinkedIn:   / medical-dialogues   Website: https://medicaldialogues.in/